Few companies garner as much reliable attention as Novo Nordisk ( NVO) does these days. With a bull market coinciding with a ...

Canada's health regulator has approved Novo Nordisk's weight loss drug Wegovy to reduce the risk of nonfatal heart attack or ...

Novo Nordisk A/S is cutting back on recruiting in Denmark after reaching the limits of its home country’s labor market in the ...

Novo Nordisk said on Monday it has launched its popular obesity drug Wegovy in China, the world's second-largest ...

Novo Nordisk faces challenges in weight-loss sector, but acquisition and strong diabetes portfolio position it for future ...

According to Reuters and CNN, Novo Nordisk announced Monday that it has launched its popular obesity drug Wegovy in China, ...

The first prescription for the drug in China will reportedly be issued at a public hospital in Shanghai this week and will ...

We came across a bullish thesis on Novo Nordisk A/S (NVO) on Long-Term Pick’s Substack by Dan. In this article, we will ...

Data from their most serious competitor, Amgen, suggests the biotech won’t upstage the market leaders.

Novo Nordisk's blockbuster weight-loss drug Wegovy is now available for use in China, the company confirmed to AFP on Tuesday ...

Novo Nordisk stock has been pretty volatile lately, making it hard to judge whether now is a good opportunity to buy shares.

Novo Nordisk (NVO) has reportedly launched its popular weight-loss drug Wegovy in China ahead of a rival drug by Eli Lilly ...